Essential hypertensive patients (176 males and 329 females), aged 58.0 ± 11.2 years were enrolled in a cross-sectional study conducted from February to March 2006 to investigate the prevalence and risk factors for microalbuminuria in hypertensive patients attending the Outpatient Department of Siriraj Hospital, Bangkok, Thailand. Macroalbuminuria was detected in 11 (2.2%) patients and microalbuminuria in 94 (18.6%) patients. Only male aged ≥ 45 years or female aged ≥ 55 years correlated significantly with a high occurrence of microalbuminuria, while calcium channel blocker and statin users were protected against microalbuminuria. The presence of microalbuminuria was not associated with age ≥ 60 years, male gender, current/previous smokers, hypertension duration ≥ 10 years, lack of blood pressure normalization, metabolic syndrome, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and multi-drug use. Risk factor recognition for microalbuminuria will enable physicians to identify cases that should be screened for microalbuminuria.
BiggaziRBianchiSBaldariD: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens1998; 16: 1325–1333.
2.
SchraderJLudersSKulschewskiA: Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: Final results of a prospective long-term study (MARPLE Study). J Hypertens2006; 24: 541–548.
VibertiG: Regression of albuminuria: Latest evidence for a new approach. J Hypertens Suppl2003; 21: S24–S28.
5.
GersteinHCMannJFYiQ: HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA2001; 286: 421–426.
6.
The InterASIA Collaborative Group: Cardiovascular risk factor levels in urban and rural Thailand—The International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Eur J Cardiovasc Prevention Rehab2003; 10: 249–257.
7.
ChobanianAVBakrisGLBlackHR: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA2003; 289: 2560–2571.
8.
AlbertiKGZimmetPShawJ: Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med2006; 23: 469–480.
9.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3421.
10.
World Health Organization: Obesity: Prevention and Managing the Global Epidemic. Report of a WHO Consultation on Obesity, Geneva: 3–5 June 1997, WHO/NUT/NCD/98.1. WHO: Geneva, 1998.
11.
JonesCAFrancisMEEberhardtMS: Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis2002; 39: 445–459.
12.
YuyunMFKhawKTLuebnR: Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol2004; 33: 189–198.
13.
ColMOcaktanEOzdemirO: Microalbuminuria: Prevalence in hypertensives and diabetics. Acta Med Austriaca2004; 31: 23–29.
14.
FischbacherCMBhopalRRutterMK: Microalbuminuria is more frequent in South Asian than in European origin populations: A comparative study in Newcastle, UK. Diabet Med2003; 20: 31–36.
15.
LuftFCAgrawalB: Microalbuminuria as a predictive factor for cardiovascular events. J Cardiovasc Pharmacol1999; 33: S11–S15.
16.
TomuraSKawadaKSaitoK: Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol1999; 19: 13–20.
17.
HallanHRomundstadSKvenildK: Microalbuminuria in diabetic and hypertensive patients and the general population—consequences of various diagnostic criteria—the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol2003; 37: 151–158.
18.
HillegeHLJanssenWMBakAA(Prevend Study Group): Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med2001; 249: 519–526.
19.
PontremoliRSofiaARaveraM: Prevalence and clinical correlates of microalbuminuria in essential hypertension: The MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension1997; 30: 1135–1143.
20.
LeveyASEckardtKUTsukamotoY: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int2005; 67: 2089–2100.
21.
ESH/ESC Hypertension Guidelines Committee: 2003 European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertens2003; 21: 1011–1053.
22.
JuliusSKjeldsenSEWeberM: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet2004; 363: 2022–2031.
23.
SinzingerHKritzHFurbergCD: Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit2003; 9: PI88–PI92.
24.
MasonJC: The statins—therapeutic diversity in renal disease?Curr Opin Nephrol Hypertens2005; 14: 17–24.
25.
ChanSCChandramaniTChenTY: Audit of hypertension in general practice. Med J Malaysia2005; 60: 475–482.
26.
OkonofuaECSimpsonKNJesriA: Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension2006; 47: 345–351.
27.
PyoralaKLehtoSDe BacquerD: Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Finding from the EUROASPIRE I and II surveys. Diabetologia2004; 47: 1257–1265.
28.
JohnsonMLPietzKBattlemanDS: Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care2006; 44: 39–46.
29.
PearsonTALauroraIChuH: The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med2000; 160: 459–467.
30.
GansevoortRTVerhaveJCHillegeHL: The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl2005; 94: s28–s35.
